Efficacy of single dose intranasal dexmedetomidine for conscious sedation in dental practice in dentophobic uncooperative patients with intellectual disability. - KUKIDEX-2

niversitair Medisch Centrum Groningen0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1. Intellectual Disability of DSM-V classes Mild to Profound
•2. Documented failure to tolerate the indicated dental treatment with non-pharmacological support.
•3. Indication for dental treatment under general anesthesia because of 1 and 2.
•4. Completed and cleared through the pre-anesthetic screening for general anesthesia as per the standard protocol of the UMCGs department of anesthesiology
•5. Adult, men and women, 18-55 years of age, inclusive.
•6. Body Mass Index (BMI) * 17.5 and * 35 kg/m2, inclusive, and a total body weight >50 kg, at screening and check-in.
•7. American Society of Anesthesiologists (ASA) Physical Status 1-3
•8. Able to understand the study procedures as described in the patient information sheet, willing and able to comply with the protocol, and to provide written informed consent OR in the case of legal incapability: a guardian understanding the study procedures as described in the patient information sheet, provides written informed consent.

•1. Contraindications for the use of dexmedetomidine
•2. Known intolerance to dexmedetomidine
•3. History or presence of significant cardiovascular disease (ASA >3), or significant cardiovascular disease risk factors, significant coronary artery disease, or any known genetic pre disposition to cardiac arrhythmia (including long QT syndrome.)
•4. History or presence of significant (ASA >3) pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological disease.
•5. History of any illness or medication use that, in the opinion of the PI, might confound the results of the study or pose an additional risk to the subject by their participation in the study.
•6 difficult airway management excpected by the attendind anesthesiologist
•7. Surgery within the past 90 days prior to dosing judged by the PI to be clinically relevant.
•8. History of febrile illness within 5 days prior to dosing.
•9. History or presence of alcoholism or drug abuse within the past 2 years.
•10. Hypersensitivity or idiosyncratic reaction to components of dexmedetomidine, , or to compounds related to the study medications.
•11. Patients refusal or, in case of legal incapability:
•12. Guardians refusal

发起方